All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The TULIP-SC trial investigated the efficacy and safety of subcutaneous Saphnelo
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Encouraging early detection and breaking the silence around men’s health
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
